

REVIEW

Open Access



# Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application

Ling Bai<sup>1</sup>, Wei Chen<sup>2</sup>, Jingtao Chen<sup>3</sup>, Wei Li<sup>1</sup>, Lei Zhou<sup>1</sup>, Chao Niu<sup>1</sup>, Wei Han<sup>1</sup> and Jiuwei Cui<sup>1\*</sup>

## Abstract

Toll-like receptor 9 (TLR9) is expressed in a variety of B-cell malignancies and works as a bridge between innate and adaptive immunity. CpG oligodeoxynucleotides (CpG ODNs), TLR9 agonists, are able to induce anticancer immune responses and exert direct effects against cancer cells, serving as cancer therapeutic agents. Therefore, TLR9 might be a potential therapeutic target for drug development. However, several new evidences have revealed that direct effects of TLR9 agonists on B-cell malignancies is controversial. For example, CpG ODNs can induce apoptosis in certain type of chronic lymphocytic leukemia and lymphoma cells, while induce proliferation in multiple myeloma and other types of lymphoma cells. In this review, we summarize current understanding of the heterogeneity in responses of normal and malignant B cells to TLR9 agonists, due to differences in TLR9 expression levels, genetic alterations (such as MyD88 mutation), and signaling pathway activation. Especially, the downstream molecules of NF- $\kappa$ B signaling pathway play an important role in the heterogeneous response. In order to provide possibilities for therapeutic manipulation of TLR9 agonists in the treatment of these disorders, the preclinical and clinical advances in using CpG ODNs alone and in combination therapies are also summarized in this review.

**Keywords:** Cancer immunotherapy, Toll-like receptor 9, B-cell malignancies, CpG oligodeoxynucleotides

## Background

B-cell malignancies are clinically and biologically heterogeneous, and they comprise a diverse spectrum of acute or chronic leukemia and lymphoma subtypes. Over the last few decades, advances in chemotherapy regimens, monoclonal antibodies, and targeted therapies have led to a dramatic improvement in the treatment of these disorders [1, 2]. The availability of specific antigens and the easy accessibility of the immune system to these diseases may make the immunotherapy of B-cell malignancies possible. Programmed cell death protein 1 (PD1) antibody and T cells with chimeric antigen receptors (CART) have been considered as promising options for treating B-cell malignancies. However, challenges still remain [3–5]. For example, some drugs are known to suppress the

immune system after long-term administration, leaving the patients highly susceptible to infection and relapse [6, 7]. Moreover, the immunotherapy of B-cell malignancies is limited to only some subtypes [8, 9]. Therefore, the identification of novel targets in malignant B cells and the development of low toxicity drugs that can induce anticancer immune responses as well as exert direct effects against cancer cells will provide new strategies for the treatment of B-cell malignancies.

Toll-like receptor 9 (TLR9) plays an important role in the innate immune system and serves as a bridge between innate and adaptive immunity in the antitumor responses [10–13]. Studies have revealed that treatment with CpG oligodeoxynucleotides (CpG ODNs), chemically synthesized TLR9 agonists, leads to tumor regression as a result of T cell- or natural killer (NK) cell-dependent lysis of tumor cells [14]. B-cell malignancies are unique because they express TLR9 and directly respond to CpG ODNs. A recent report has demonstrated that CpG ODNs induce the apoptosis of B-cell chronic lymphocytic leukemia

\*Correspondence: cuijw@jlu.edu.cn

<sup>1</sup> Cancer Center, The First Bethune Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China

Full list of author information is available at the end of the article

(B-CLL) [15]. Moreover, in contrast to other immune adjuvants, CpG ODNs, administered as an in situ vaccination, have effects on both the immune system and B-cell malignancies [15–18]. Increasing evidence has shown that TLR9 expression on B-cell malignancies exhibits high heterogeneity and that the activation of TLR9 elicits the opposite biological effects [19–21]. For example, CpG ODNs induce apoptosis in some types of human Burkitt lymphoma [22] but enhance the proliferation of malignant B cells in multiple myeloma (MM) [23] and some types of lymphoma [10, 24]. Furthermore, some B-cell lymphomas have no effect during CpG stimulation [25].

The heterogeneity of TLR9 expression on B-cell malignancies and their heterogeneous response to CpG ODNs may provide new targeted therapies against cancerous B cells. The responses of different cancerous B cells to CpG ODNs will determine the appropriate treatment for different B-cell malignancies. However, whether or not TLR9 could serve as a therapeutic target for human B-cell malignancies remains unknown. This review discusses the multiple roles of TLR9 signaling in B-cell malignancies as reported in recent preclinical and clinical studies. Better understanding of the diverse roles of TLR9 signaling will facilitate evaluation of the potential utility of TLR9 as a therapeutic target in the treatment of B-cell malignancies.

#### Multiple effects of TLR9-mediated responses

Toll-like receptors (TLRs) are important sensors of foreign microbial components and products of damaged or inflamed self-tissue. The TLRs include at least 10 types of integral membrane glycoproteins in humans that recognize a diverse array of ligands, including bacterial lipopolysaccharides, RNAs, and DNAs. Among these TLRs, TLR9 detects the unmethylated CpG dinucleotides present in viral and prokaryotic genomes, whereas these dinucleotides are generally methylated in host DNA [5, 26]. TLR9 is mainly expressed in the endoplasmic reticulum of human plasmacytoid dendritic cells (pDCs) and B cells, and induces the recruitment of myeloid differentiation antigen 88 (MyD88) to initiate the activation of nuclear factor (NF)- $\kappa$ B, c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) signaling pathways by binding to its ligand in endocytic vesicles.

The binding of TLR9 to its ligand also activates interferon regulatory factor-7, resulting in the secretion of type I interferons (IFNs) by pDCs and further promoting pDC maturation [27–29]. Type I IFNs subsequently activate NK cells, natural killer T cells, monocytes, and induce cytotoxic lymphocyte (CTL) and T helper-1 (Th1) responses (Fig. 1). In normal B cells, TLR9 activation increases interleukin (IL) -6 and IL-10 synthesis as well as cell proliferation, immunoglobulin secretion, and

plasma cell differentiation (Fig. 1) [30–34]. Although the secretion of IL-10 contributes to B-cell proliferation and “Th1-like” isotype switch, it suppresses the antigen presentation activities and the secretion of Th1-like cytokines (such as IL-12 and IFNs) of pDCs [34–36]. And recent studies indicate that TLR9 can also be expressed on the cell surface of B-cell lymphocytes, serving as a negative regulator of endosomal TLR9 activation [37].

TLR9 stimulation by CpG ODNs appears to induce a strong Th1-type immune response that is therapeutically important for antitumor and antiviral immunities. On the other hand, the increased expression of indoleamine 2,3-dioxygenase in mature pDCs may result in the generation of inducible regulatory T cells (Tregs) from naive T cells. These Tregs play a critical role in maintaining the balance of the immune system [38–41] through secreting IL-10 and transforming growth factor- $\beta$ .


TLR9 activation also leads to the upregulation of chemokine receptor 7, which causes cell trafficking to the T-cell zone of lymph nodes [42] as well as antigen-presenting molecules (major histocompatibility complex (MHC) class I and II) and costimulatory molecules (CD80, CD86, and CD40), thereby promoting antigen presentation by pDCs and B-cells [11]. Consistent with these findings, a strong synergy has been reported between CD40 ligands and TLR9 agonists in B-cell differentiation [43].

However, the relationship between the TLR9-mediated signaling pathways and cell surface molecules remains unclear. A limited number of experiments have shown that CD19 is a primary costimulatory molecule that amplifies B-cell receptor responses and that CpG ODNs induce CD19 phosphorylation through MyD88/phosphatidylinositol 3-kinase/AKT and Bruton's tyrosine kinase (BTK) activation in human B cells [44]. Furthermore, BTK inhibitors can block the activation of CD86 and MHC class II by CpG ODNs, suggesting the involvement of BTK in the upregulation of surface molecules in B cells in response to CpG ODNs [45].

In sum, TLR9 mediates both positive and negative immune regulation, which keeps the homeostasis of the immune system [40, 46]. By understanding the deliberate regulation of TLR9 signaling pathways in immune cells as well as malignant B cells, it will help us facilitate manipulating the immune effects of CpG ODNs, such as enhancing antitumor effects in the treatment of cancer and simultaneously avoiding overactive immune response.

#### Development of CpG ODN-based drugs as therapeutic agents for B-cell malignancies

Because of multiple immunomodulatory effects, the TLR9 pathway has received increasing attention for the development of cancer therapeutic strategies. TLR9 is



stimulated by its ligand-CpG motifs delivered in the form of CpG ODNs that are optimized for their stimulatory activity. These ligands can be chemically synthesized and used as highly selective triggers to stimulate particular subsets of immune cells. Three classes of CpG ODNs have been identified: Class A (Type D), Class B (Type K), and Class C. Class B CpG ODN (CpG-B ODN) is the most efficient in inducing naive B cell (CD19<sup>+</sup>CD27<sup>+</sup>) activation and proliferation [30]. Class C CpG ODN (CpG-C ODN), which exhibits characteristics of both

Class A and Class B CpG ODNs, appears to induce more efficient IFN- $\alpha$  secretion than CpG-B ODNs [47–50]. Both CpG-B ODNs and CpG-C ODNs induce a potent Th1-based immune response, leading to comparable antibody production in addition to CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses.

In addition to the high effectiveness of CpG-B ODNs for the treatment of B-cell malignancies, CpG-B ODNs (e.g., CpG7909 and GNKG168), as immune adjuvants, have demonstrated excellent safety profiles without

dose-limiting, end-organ toxicity, significant laboratory toxicity, and severe adverse effects in over 100 clinical trials. As the development of CpG-based therapy, strategies have been applied to maximize the therapeutic effects of CpG-based drugs, such as prolonging the drug half-life, increasing the cellular uptake and binding, enhancing the drug biological activity, protecting against nuclease degradation [51, 52]. According to the natural capability of certain cells to recognize CpG ODNs, CpG-siRNA/decoyODN conjugates have been harnessed for cell-specific siRNA delivery [53, 54].

Thus, with the development of novel CpG-based agents, it might enhance the direct and indirect effects on cancer cells, which will provide more potential of CpG ODNs in the clinical application.


### TLR9 expression and responses to CpG-B ODNs in normal B-cell subsets

B-cell differentiation, an important step in immune responses against invading pathogens, often involves a germinal center B-cell response, eventually leading to the generation of antibody-producing plasma cells. In addition, other subtypes of B cells, such as peripheral blood-derived naive B cells, germinal center B cells, etc., express

different levels of TLR9 [10, 55]. Moreover, higher levels of TLR9 expression are observed in tonsillar B cells than in circulating blood B cells [56]. These findings demonstrate that the differentiation stage has an impact on the expression of TLR9 (Fig. 2). For example, memory B cells express higher levels of TLR9 than naive B cells or germinal center B cells [10]. Some studies suggest that TLR9 expression is related to the level of the B-cell receptor, whose expression is increased with the differentiation of B cells [57]. In addition, a recent study also has shown that newborn naive B cells have a higher TLR9 expression level than adult naive B cells [58]. Although CpG ODNs induce proliferation in human and murine B cells by promoting the cells from G1-phase into S-phase [59, 60], the direct relationship between the response mediated by CpG ODNs and the expression of TLR9 in normal B-cell subsets remains elusive, and needs further study.

### Heterogeneity of TLR9 expression and responses to CpG ODNs in B-cell malignancies

Some B-cell malignancies are characterized by a normal B-cell precursor phenotype, such as CD10 expression. Previous studies have shown that TLR9 is expressed at almost all stages of B cell development [61]. Like normal



**Fig. 2** The expression of TLR9 in normal B cells and B-cell malignancies. TLR9 is expressed heterogeneously at almost all stages of B cell development. B cell precursors (+◇) grown in *Iscove's modified Dulbecco's media* with recombinant IL-7 express different levels of TLR9. Memory B cells express higher levels of TLR9 (+++) than naive B cells (+) and germinal center B cells (++) . In addition, B cell malignancies arising from different stages of B cells also express TLR9. Although the exact expression levels of TLR9 in these cells remain unknown, activation of TLR9 causes surface marker upregulation and cytokine secretion according to in vitro experiments (+\*) and clinical data (+△) (*CLL* chronic lymphocytic leukemia, *BL* Burkitt lymphoma, *NHL* non-Hodgkin lymphoma, *MM* multiple myeloma, *GC B cells* germinal center B cells, *FL* follicular lymphoma, *DLBCL* diffuse large B cell lymphoma, *MZLs* marginal zone lymphomas, *MCL* mantle cell lymphoma, *pre-B cells* precursor B cells, *SLL* small lymphocytic lymphoma, *ALL* acute lymphocyte leukemia)




B cells, B-cell malignancies arising from different stages of B cell development also express TLR9 (Fig. 2). However, recent study indicates that TLR9 expression levels of B-cell malignancies are different from normal B cells [62]. Furthermore, the TLR9 expression in malignant B cells is heterogeneous in each cancer subtype, even in individual patients. Although the heterogeneity of TLR9 expression in some B-cell malignancies remains to be determined, the degree of TLR9-mediated B-cell activation might depend on the expression of TLR9 in B-cell malignancies [63]. However, this is not the case in some instances. For example, despite the same levels of TLR9 expression, memory B cell-related marginal zone lymphomas showed the higher induction of proliferation following stimulation by TLR9 agonists compared to follicular lymphomas and diffuse large B cell lymphomas (DLBCLs) derived from germinal center B cells. Thus, even similar TLR9 expression levels have different responses to TLR9 activation [64].

In addition to the differential expression of TLR9 in normal or cancerous B cells, heterogeneous responses to CpG ODNs also have been observed. Like normal B cells, malignant B cells exhibit heterogeneous responses to CpG ODNs. They can induce either proliferation or apoptosis of different types of cancerous B cells. Clinical data indicate that CpG ODNs can induce the proliferation of marginal zone lymphomas, follicular lymphomas, small lymphocytic lymphomas, diffuse large B cell lymphomas, as well as B-CLL cells from patients with progressive disease and non-mutated  $V_H$  genes [65]. In contrast, CpG ODNs induce apoptosis of B-CLL cells from patients with stable disease and mutated  $V_H$  genes. However, CpG ODNs do not have effects on some mantle cell lymphoma cells [63, 66].

Elucidation of the molecular mechanisms underlying the heterogeneity of the TLR9 response may provide a valuable clue for the application of CpG ODNs in the treatment of B-cell malignancies. The TLR9 signaling in malignant B cells mainly involves the NF- $\kappa$ B or MAPK signaling pathway. NF- $\kappa$ B, the major nuclear heterodimer, is expressed and activated in human primary B cells. Its activation exerts both anti-apoptotic and pro-apoptotic effects in response to TLR9 agonists stimulation [67], depending on the downstream molecules of the NF- $\kappa$ B signaling pathway [68]. For instance, if NF- $\kappa$ B is involved in activation of Ras-dependent MAPK cascades and the janus kinase/signal transducers and activators of transcription 3 (JAK/STAT3) signaling pathway, activation will result in the proliferation of IL-6-processed MM [23, 69]. If NF- $\kappa$ B induces phosphorylation and activation of the signal transducer and activator of transcription 1 (STAT1) in B-CLL cells, cleavage and apoptosis are induced via the activation of caspases

and poly(ADP-ribose) polymerase [15] (Fig. 3). TLR9 responses to CpG ODNs are also associated with  $V_H$  gene mutations. The subset of B-CLL samples without a  $V_H$  gene mutation show strong and durable activation of AKT, MAPK, and NF- $\kappa$ B to CpG ODNs stimulation [65, 70]. Recent research indicates that the apoptosis of B-CLL cells induced by CpG ODNs can be reversed by IL-15- or IL-2-induced Extracellular Signal-Regulated Kinase (ERK) 1/2 and AKT phosphorylation as well as Bcl-2 upregulation [71]. This function may be associated with several chromosomal abnormalities [72]. But in some situation, the gene and protein expression levels may also influence the outcomes of B-cell malignancies upon CpG ODNs treated. For instance, associated with interleukin-10 stimulation, CpG ODNs drive B-cell lymphomas with low c-Myc expression levels proliferation through the activation of both NF- $\kappa$ B and STAT3 signaling pathway and further increasing the expression of the cyclin-dependent kinase 4 [73]. Similarly, another study shows that CpG ODNs trigger sustained increases in NF- $\kappa$ B activation in mouse primary B cells, which also express low levels of c-Myc, thus stimulating the proliferation of primary B cells and the rescue of the B cells from spontaneous apoptosis. However, CpG ODNs could induce cell apoptosis in the cells with overexpression of c-Myc. For example, in the mouse B-cell lymphoma cell line CH27, because of the high expression levels of c-Myc, CpG ODNs trigger a transient NF- $\kappa$ B activation eventually inducing apoptosis via Fas/Fas ligand apoptotic pathway (Fig. 3) [74].

As a key regulator in the TLR9 signaling pathway, the MyD88 mutation is one of the common mutations in B-cell malignancies. Four MyD88 mutations, L265P (Mut1), S219C (Mut2), M232T (Mut4), and S243N (Mut5), have been reported to promote B-cell proliferation. The L265P mutation occurs in 29% of activated B cell-like diffuse large B-cell lymphomas, >90% of Waldenstrom's macroglobulinemia, and other B-cell lymphoma patients [75]. This mutation causes uncontrolled formation of the protein complex IRAK1/4 and induction of Bruton's tyrosine kinase signaling, ultimately leading to NF- $\kappa$ B overactivation, elevated levels of STAT3 phosphorylation, IL-6, IL-10, and IFN- $\beta$  secretion, and subsequent enhanced survival of MyD88 L265P Waldenstrom's macroglobulinemia cells [75, 76]. A clinical study is currently underway to confirm these findings [77]. In addition, mutations in the TLR/MyD88 pathway, which occur in 4% of CLL patients, can enhance the gene expression of the NF- $\kappa$ B pathway, consistent with the prediction of outcome [78]. But it remains unclear whether MyD88 mutations impact the sensitivity of B-CLL cells to CpG ODNs stimulation. Therefore, further studies are required to determine whether mutations in TLR9 and



its downstream signaling pathway are correlated with different cancerous B cells. Even the same type of malignant B cells may respond differently to CpG ODNs stimulation, using different downstream signaling pathways. For instance, Epstein–Barr virus-negative Burkitt lymphoma Akata31 cells exhibit more extensive apoptosis than Epstein–Barr virus-positive Akata cells following CpG 2006 stimulation. This difference may be due to the single nucleotide polymorphisms (rs5743836 and rs352140) within the TLR9 gene in Akata cells [22].

Malignant B cells also show heterogeneous cytokine secretion and costimulatory molecule expression responding to CpG ODNs stimulation. Following CpG ODNs stimulation, the expression levels of CD40, CD54, CD80, CD86, and MHC class I and II are all significantly increased in B-CLL cells [11], whereas only the expression of CD40 is significantly upregulated in acute lymphocyte leukemia cells [21]. However, in mantle cell lymphoma cells, upregulation of CD80, CD86, and MHC class I is not observed. DLBCL cells also show no increase in the expression of MHC class I and II [63].

In summary, different cancerous B cells will respond differently to TLR9 stimulation because of genetic alterations. The heterogeneous responses of B-cell malignancies to TLR9 stimulation remain a challenge for the clinical application of CpG ODN-based therapies. Further investigation is required to examine the expression profiles of TLR9 and the mechanisms underlying the heterogeneous response to TLR9 stimulation in malignant B cells. Characterization of these profiles and pathways may improve the efficacy of CpG ODNs treatment in combination with specific pharmacological inhibitors.

#### Potential therapeutic effects of CpG ODNs in B-cell malignancies

Above all, the TLR9 agonists demonstrates direct effects on certain types of malignant cells, besides its stimulating effects on immune response. It has shown therapeutic potential of TLR9 agonists alone and in combination therapies in B-cell malignancies in vitro and in vivo studies.

Several clinical and preclinical trials have demonstrated that CpG ODNs have direct antitumor effects in monotherapy. For example, an in vitro study has demonstrated that CpG 685, a Class B CpG ODN, induces apoptosis of CLL cells via activation of NF- $\kappa$ B [15]. Moreover, a recent phase I study of CpG 7909 (PF-3512676) [31] in patients with early relapsed CLL has revealed that a multiple weekly subcutaneous dose of 0.45 mg/kg body weight is well tolerated, indicating that multi-dose direct effects on B-cell malignancies. Furthermore, it has no toxicity against normal cells and also shows its activating effects on immune system [64, 79].

Some studies have also shown CpG ODNs' indirect effects on malignant B cells by activating antitumor immune responses. Intravenous administration of CpG 7909 at dose levels 0.01–0.64 mg/kg three times a week was found to elicit an increased NK cell number and induce NK cell activation in patients with refractory non-Hodgkin lymphoma [80]. Additionally, in some types of B-cell malignancy, CpG ODNs have no direct proapoptotic effects on the malignant B cells and only have immune effects in some cases. CpG ODNs have been shown to induce pDCs maturation to secrete IFN- $\alpha$  and IFN- $\lambda$ , which results in G2-phase arrested in MM cells co-cultured with pDCs. Instead, there is no direct effects on MM cells treated with CpG ODNs alone in vitro [81–84]. Therefore, TLR9 agonists could perform its therapeutic potentiality on B-cell malignancies through the host immune cells and/or direct effects on the tumor cells [17].

In addition to being an efficacious single agent, CpG ODNs show synergetic effects with other therapies such as chemotherapy, radiotherapy, and target therapy. In the

studies of combination of CpG ODNs with chemotherapy agent cyclophosphamide (CTX), the combination group showed better outcome in the patients with lymphoma compared with using CpG ODNs or CTX alone. CTX can directly inhibit the tumor growth and give time for the activation of CD8<sup>+</sup> T cells mediated by CpG ODNs. Moreover, CTX may inhibits the ratio of tumor-infiltrating Treg cells, so that it breaks the homeostasis of the immune system and further enhances the Th1 response. [17] These similar synergetic effects have also been discovered in other types of tumors, with increased survival time [85–88].

Apart from improving the chemotherapeutic agents' effects, CpG ODNs also improve radiotherapy outcomes of both immunogenic and non-immunogenic with a high complete tumor remission rate [17, 89] by exerting direct effects on human malignant B cells and indirect effects on the immune system with an increase in the number of tumor-reactive memory CD8<sup>+</sup> T cells, leading to enhanced antitumor immunity [18, 90, 91]. Besides, the treatment was well tolerated. Additionally, CpG ODNs can protect normal B cells from irradiation-induced cell death and enhance macrophages viability even after irradiation. And this protection may be associated with the upregulation of anti-apoptotic molecules, such as Bcl-x/L and Bcl-2 in these cells [92]. Thus, it indicates that CpG ODNs can improve radioresistance of the normal immune cells.

Furthermore, CpG ODNs can increase the sensitivity of tumor cells to antibody-dependent cellular cytotoxicity (ADCC) lysis, and potentiate cytotoxicity of ADCC effectors. The activation and expansion of Fc receptor-bearing NK cells through cytokines secretion (such as IL-12) mediated by CpG ODNs may increase the efficacy of rituximab. It has been demonstrated that CpG ODNs, when administered in combination with the CD20 antibody, can enhance the efficiency of rituximab in killing Daudi non-Hodgkin lymphoma cell lines. Besides, the upregulation of CD20 expression levels mediated by CpG ODNs might further promotes the killing effects by rituximab [80, 93]. This effect has also been confirmed in murine lymphoma models. CpG ODNs also can be used as adjuvants for anti-idiotypic vaccines to increase the efficiency of monoclonal antibody therapy, depending on the TLR9 expression in host immune cells [94, 95]. Furthermore, rituximab plus intratumoral CpG ODNs, but not systemic CpG ODNs, eradicate up to half of 7-day established 38C13-huCD20 tumors, a syngeneic murine B cell lymphoma expressing human CD20. Additionally, brief and extended-duration administration of CpG 7909 in combination with rituximab has been found to be safe in patients with relapsed/refractory non-Hodgkin lymphoma [96].

To increase the cell specific activity, CpG-siRNA/decoyODN conjugates provide a novel therapeutic strategy. For instance, STAT3 plays an important role in both cancer cells and tumor-associated immune cells to promote cancer progression and survival with upregulation of BCL-XL protein expression. CpG-STAT3siRNA conjugates shows a better effect not only on the direct killing but also on immune-mediated eradication compared with using CpG ODNs alone in hematologic malignancies with upregulating costimulatory and proinflammatory molecules, downregulating PD-L1 molecule, and increasing the ratio of tumor-infiltrating CD8<sup>+</sup> T cells [53, 54].

In short, despite the fact that the use of CpG ODNs alone or in combination therapies showed a satisfactory treatment effect in B-cell malignancies, CpG ODNs do not have proapoptotic or antitumor effects in some cases [84]. Thus, it suggests that the care should be taken regarding the application of CpG ODNs in B-cell lymphoma treatment. Accordingly, future studies should aim to elucidate the expression profiles of TLR9 in B-cell malignancies, develop other types of CpG ODNs, and design combination therapies with CpG ODNs for the treatment of B-cell malignancies.

### Conclusion and prospects

CpG ODNs exert multiple effects on the immune system in addition to direct effects on B-cell malignancies. Numerous preclinical and clinical trials have demonstrated the safety and efficacy of CpG ODNs in the treatment of several B-cell malignancies, indicating that TLR9 represents a promising target for the treatment of such disorders. However, some studies have reported that CpG ODN-based therapies elicit tumor-promoting effects. Therefore, the heterogeneous expression of TLR9 and differential effects of CpG ODNs in different B-cell malignancies require further investigation. In addition, CpG ODNs act synergistically with other therapies, and potential combination therapeutic strategies for the treatment of B-cell malignancies may thus achieve the desired outcomes. The use of combination therapies and CpG ODNs administration as an in situ vaccination would maximize the clinical benefit. As a result, deepening the understanding of the oncogenic mechanisms in B-cell malignancies will enable matching treatments with the cancer genotype, thus providing further possibilities for the therapeutic manipulation of TLR9 as a target for the precise treatment of B-cell malignancies.

### Abbreviations

TLR9: Toll-like receptor 9; TLRs: Toll-like receptors; mAbs: monoclonal antibodies; CpG ODN: CpG oligodeoxynucleotide; MyD88: myeloid differentiation

antigen 88; PD1: programmed cell death protein 1; CART: T cells with chimeric antigen receptors; JNK: c-Jun N-terminal kinase; CTL: cytotoxic lymphocyte; IFN: interferon; IL: interleukin; MHC: major histocompatibility complex; Th1: T helper-1; NK: natural killer; ALL: acute lymphocyte leukemia; CLL: chronic lymphocytic leukemia; MM: multiple myeloma; DLBCLs: diffuse large B cell lymphomas; pDCs: plasmacytoid dendritic cells; CTX: cyclophosphamide; NF: nuclear factor; MAPK: mitogen-activated protein kinases; BTK: Bruton's tyrosine kinase; JAK: janus kinase/signal transducers; ERK: Extracellular Signal-Regulated Kinase; STAT3: signal transducer and activator of transcription 3; STAT1: signal transducer and activator of transcription 1; ADCC: antibody-dependent cellular cytotoxicity.

### Authors' contributions

LB carried out the primary literature search and analysis, drafted and revised the manuscript. WC helped the modification of the manuscript. JTC and WL contributed to the coordination and helped to draft the manuscript. LZ, CN, and WH participated in discussions and literature search. JWC carried out the design of the research and literature analysis, drafted and revised the manuscript. All authors read and approved the final manuscript.

### Author details

<sup>1</sup> Cancer Center, The First Bethune Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China. <sup>2</sup> ADC Biomedical Research Institute, 1919 University Avenue, Saint Paul, MN 55104, USA. <sup>3</sup> Institute of Translational Medicine, The First Bethune Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China.

### Acknowledgements

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its additional files.

### Funding

This work was supported by the Jilin Provincial Science and Technology Department (Grants 20111807 and 20140414014GH, and 20150101176 to JWC), the Platform Construction Project of Development and Reform Commission of Jilin Province (Grant 2014N147 to JWC), the Bethune Program B of Jilin University (Grant 2012202 to JWC), the National Major Scientific and Technological Special Project (Grant 2013ZX09102032 to JTC), and the Key Scientific Project of Jilin Province (20140204024YY to JTC).

Received: 28 November 2016 Accepted: 17 February 2017

Published online: 27 February 2017

### References

1. Arnason JE, Brown JR. Targeted therapy for chronic lymphocytic leukemia: current status and future directions. *Drugs*. 2015;75:143–55.
2. Rossi JF. Targeted therapies in adult B-cell malignancies. *Biomed Res Int*. 2015;2015:217593.
3. Finn OJ. Cancer vaccines: between the idea and the reality. *Nat Rev Immunol*. 2003;3:630–41.
4. Naddafi F, Davami F. Anti-CD19 monoclonal antibodies: a new approach to lymphoma therapy. *Int J Mol Cell Med*. 2015;4:143.
5. Bird AP. CpG-rich islands and the function of DNA methylation. *Nature*. 1986;321:209–13.
6. Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, et al. Proteasome inhibition suppresses essential immune functions of human CD4<sup>+</sup> T cells. *Immunology*. 2008;124:234–46.
7. Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. *Nat Chem Biol*. 2011;7:41–50.
8. Zappasodi R, de Braud F, Di Nicola M. Lymphoma immunotherapy: current status. *Front Immunol*. 2015;6:448.



9. Lorentzen CL, Straten PT. CD19-chimeric antigen receptor t cells for treatment of chronic lymphocytic leukaemia and acute lymphoblastic leukaemia. *Scand J Immunol*. 2015;82:307–19.
10. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G. Toll-like receptors: lessons to learn from normal and malignant human B cells. *Blood*. 2008;112:2205–13.
11. Jahrsdörfer B, Hartmann G, Racila E, Jackson W, Mühlenhoff L, Meinhardt G, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. *J Leukoc Biol*. 2001;69:81–8.
12. Agrawal S, Gupta S. TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. *J Clin Immunol*. 2011;31:89–98.
13. Sabroe I, Parker LC, Dower SK, Whyte MKB. The role of TLR activation in inflammation. *J Pathol*. 2008;214:126–35.
14. Maruyama K, Selmani Z, Ishii KH, Yamaguchi K. Innate immunity and cancer therapy. *Int Immunopharmacol*. 2011;11:350–7.
15. Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR, et al. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. *Blood*. 2010;115:5041–52.
16. Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y, et al. TLR9 signaling promotes tumor progression of human lung cancer cell in vivo. *Pathol Oncol Res*. 2009;15:623–30.
17. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. *J Immunol*. 2007;179:2493–500.
18. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. *J Clin Oncol*. 2010;28:4324–32.
19. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. *Science*. 2007;317:124–7.
20. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demonstration of inflammation-induced cancer and cancer immunoevasion during primary tumorigenesis. *Proc Natl Acad Sci USA*. 2008;105:652–6.
21. Corthals SL, Wynne K, She K, Shimizu H, Curman D, Garbutt K, et al. Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. *Br J Haematol*. 2006;132:452–8.
22. Noack J, Jordi M, Zauner L, Alessi D, Burch A, Tinguely M, et al. TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism. *Cell Death Dis*. 2012;3:e323.
23. Bohnhorst J, Rasmussen T, Moen SH, Fløttum M, Knudsen L, Børset M, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. *Leukemia*. 2006;20:1138–44.
24. Henault M, Lee LN, Evans GF, Zuckerman SH. The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides. *J Immunol Methods*. 2005;300:93–9.
25. Buhé V, Guerrier T, Youinou P, Berthou C, Loisel S. CpG ODN enhances the efficacy of rituximab in non-Hodgkin lymphoma. *Ann NY Acad Sci*. 2009;1173:858–64.
26. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. *Nat Immunol*. 2001;2:675–80.
27. Guiducci C, Ghirelli C, Marloie-Provost MA, Matray T, Coffman RL, Liu YJ, et al. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid dendritic cells in response to TLR activation. *J Exp Med*. 2008;205:315–22.
28. Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. *Adv Drug Deliv Rev*. 2008;60:795–804.
29. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. *Immunity*. 2006;25:349–60.
30. Jiang W, Lederman MM, Harding CV, Rodriguez B, Mohner RJ, Siegf SF. TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. *Eur J Immunol*. 2007;37:2205–13.
31. Eckl-Dorna J, Batista FD. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. *Blood*. 2009;113:3969–77.
32. Von Glehn F, Santos LM, Balashov KE. Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis. *Immunotherapy*. 2012;4:1053–61.
33. Huang X, Yang Y. Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses. *Expert Opin Ther Targets*. 2010;14:787–96.
34. Peng SL. Signaling in B cells via Toll-like receptors. *Curr Opin Immunol*. 2005;17:230–6.
35. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. *Immunol Rev*. 2007;220:251–69.
36. Gray M, Gray D. Regulatory B cells mediate tolerance to apoptotic self in health: implications for disease. *Int Immunol*. 2015;27:505–11.
37. Guerrier T, Pochard P, Lahiri A, Youinou P, Pers JO, Jamin C. TLR9 expressed on plasma membrane acts as a negative regulator of human B cell response. *J Autoimmun*. 2014;51:23–9.
38. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4<sup>+</sup> CD25<sup>+</sup> T cell-mediated suppression by dendritic cells. *Science*. 2003;299:1033–6.
39. Yang Y, Huang X, Huang CT, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. *Nat Immunol*. 2004;5:508–15.
40. Conroy H, Marshall NA, Mills KHG. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. *Oncogene*. 2008;27:168–80.
41. Puccetti P. On watching the watchers: IDO and type I/II IFN. *Eur J Immunol*. 2007;37:876–9.
42. Van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. *Trends Immunol*. 2006;27:49–55.
43. Wagner M, Poeck H, Jahrsdoerfer B, Rothenfusser S, Prell D, Bohle B, et al. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. *J Immunol*. 2004;172:954–63.
44. Morbach H, Schickel JN, Cunningham-Rundles C, Conley ME, Reisli I, Franco JL, et al. CD19 controls Toll-like receptor 9 responses in human B cells. *J Allergy Clin Immunol*. 2016;137:889–98.
45. Kenny EF, Quinn SR, Doyle SL, Vink PM, van Eenennaam H, O'Neill LA. Bruton's tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin. *PLoS ONE*. 2013;8:e74103.
46. Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. *Ann NY Acad Sci*. 2010;1183:89–103.
47. Carpentier AF. Cancer immunotherapy with CpG-ODN. *Med Sci (Paris)*. 2005;21:73–7.
48. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. *J Immunol*. 2001;166:2372–7.
49. Rothenfusser S, Tuma E, Endres S, Hartmann G. Plasmacytoid dendritic cells: the key to CpG. *Hum Immunol*. 2002;63:1111–9.
50. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. *Eur J Immunol*. 2004;34:251–62.
51. Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. *J Control Release*. 2004;97:1–17.
52. Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. *Mol Pharmacol*. 1994;45:932–43.
53. Hossain DMS, Dos Santos C, Zhang Q, Kozłowska A, Liu H, Gao C, et al. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. *Blood*. 2014;123:15–25.
54. Zhang Q, Hossain DMS, Nechaev S, Kozłowska A, Zhang W, Liu Y, et al. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. *Blood*. 2013;121:1304–15.
55. Dorner T, Radbruch A. Antibodies and B cell memory in viral immunity. *Immunity*. 2007;27:384–92.
56. Månsson A, Adner M, Höckerfelt U, Cardell LO. A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation. *Immunology*. 2006;118:539–48.
57. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. *Blood*. 2003;101:4500–4.
58. Pettengill MA, van Haren SD, Li N, Dowling DJ, Bergelson I, Jans J, et al. Distinct TLR-mediated cytokine production and

- immunoglobulin secretion in human newborn naive B cells. *Innate Immun.* 2016;22:433–43.
59. Yi AK, Chang M, Peckham DW, Krieg AM, Ashman RF. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. *J Immunol.* 1998;160:5898–906.
  60. Nikitin PA, Price AM, McFadden K, Yan CM, Luftig MA. Mitogen-induced B-cell proliferation activates Chk2-dependent G1/S cell cycle arrest. *PLoS ONE.* 2014;9:e87299.
  61. Azulay-Debby H, Edry E, Melamed D. CpG DNA stimulates autoreactive immature B cells in the bone marrow. *Eur J Immunol.* 2007;37:1463–75.
  62. Jahrsdorfer B, Mühlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. *Clin Cancer Res.* 2005;11:1490–9.
  63. Sanchez-Cuaxospa M, Contreras-Ramos A, Perez-Figueroa E, Medina-Sanson A, Jimenez-Hernandez E, Torres-Nava JR, et al. Low expression of Toll-like receptors in peripheral blood mononuclear cells of pediatric patients with acute lymphoblastic leukemia. *Int J Oncol.* 2016;49:675–81.
  64. Guerrier T, Youinou P, Pers JO, Jamin C. TLR9 drives the development of transitional B cells towards the marginal zone pathway and promotes autoimmunity. *J Autoimmun.* 2012;39:173–9.
  65. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. *Leukemia.* 2007;21:110–20.
  66. Zent CS, Smith BJ, Ballas ZK, Wooldridge JE, Link BK, Call TG, et al. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. *Leuk Lymphoma.* 2012;53:211–7.
  67. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. *J Immunol.* 2000;164:944–53.
  68. Farhana L, Dawson MI, Fontana JA. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappaB activation. *Cancer Res.* 2005;65:4909–17.
  69. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. *J Immunol.* 1997;159:2212–21.
  70. Arvaniti E, Ntoufa S, Papakonstantinou N, Touloumenidou T, Laoutaris N, Anagnostopoulos A, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. *Haematologica.* 2011;96:1644–52.
  71. Chatzouli M, Ntoufa S, Papakonstantinou N, Chartomatsidou E, Anagnostopoulos A, Kollia P, et al. Heterogeneous functional effects of concomitant B cell receptor and TLR stimulation in chronic lymphocytic leukemia with mutated versus unmutated Ig genes. *J Immunol.* 2014;192:4518–24.
  72. Mongini PK, Gupta R, Boyle E, Nieto J, Lee H, Stein J, et al. TLR-9 and IL-15 synergy promotes the in vitro clonal expansion of chronic lymphocytic leukemia B cells. *J Immunol.* 2015;195:901–23.
  73. Feist M, Kemper J, Taruttis F, Rehberg T, Engelmann JC, Gronwald W, et al. Synergy of interleukin 10 and Toll-like receptor 9 signalling in B cell proliferation: implications for lymphoma pathogenesis. *Int J Cancer.* 2017;104:1147–58.
  74. Arunkumar N, Liu C, Hang H, Song W. Toll-like receptor agonists induce apoptosis in mouse B-cell lymphoma cells by altering NF-kappaB activation. *Cell Mol Immunol.* 2013;10:360–72.
  75. Wang JQ, Jeelall YS, Beutler B, Horikawa K, Goodnow CC. Consequences of the recurrent MYD88 (L265P) somatic mutation for B cell tolerance. *J Exp Med.* 2014;211:413–26.
  76. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. *Nature.* 2011;470:115–9.
  77. Ntoufa S, Vilia MG, Stamatopoulos K, Ghia P, Muzio M. Toll-like receptors signaling: a complex network for NF-kappaB activation in B-cell lymphoid malignancies. *Semin Cancer Biol.* 2016;39:15–25.
  78. Martínez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, et al. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. *Blood.* 2014;123:3790–6.
  79. Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bossler AD, Shannon M, et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. *J Immunother.* 2006;29:558–68.
  80. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, et al. Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-Hodgkin's lymphoma. *Clin Cancer Res.* 2007;13:6168–74.
  81. Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. *Cancer Cell.* 2009;16:309–23.
  82. Cottini F, Anderson K. Novel therapeutic targets in multiple myeloma. *Clin Adv Hematol Oncol.* 2015;13:236–48.
  83. Ray A, Tian Z, Das DS, Coffman RL, Richardson P, Chauhan D, et al. A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib. *Leukemia.* 2014;28:1716–24.
  84. Abdelwahed RB, Cosette J, Donnou S, Crozet L, Ouakrim H, Fridman WH, et al. Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. *J Exp Clin Cancer Res.* 2013;32:18.
  85. Weber JS, Zarour H, Redman B, Trefzer U, O'day S, van den Eertwegh AJ, et al. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. *Cancer.* 2009;115:3944–54.
  86. Leichman G, Gravenor D, Albert G, Schmalbach T. A TLR9 CpG immunomodulator in combination with chemotherapy as treatment for advanced non-small cell lung cancer (NSCLC), a randomized, controlled phase II study. *J Clin Oncol.* 2004;22:7126.
  87. Jordan M, Waxman DJ. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. *Cancer Lett.* 2016;373:88–96.
  88. Jahrsdörfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. *Update Cancer Ther.* 2008;3:27–32.
  89. Mason KA, Neal R, Hunter N, Ariga H, Ang K, Milas L. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. *Radiother Oncol.* 2006;80:192–8.
  90. Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, et al. CpG oligodeoxynucleotide enhances tumor response to radiation. *Cancer Res.* 2004;64:5074–7.
  91. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. *Clin Cancer Res.* 2005;11:361–9.
  92. Sohn WJ, Lee KW, Choi SY, Chung E, Lee Y, Kim TY, et al. CpG-oligodeoxynucleotide protects immune cells from  $\gamma$ -irradiation-induced cell death. *Mol Immunol.* 2006;43:1163–71.
  93. Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. *J Immunother.* 2009;32:622–31.
  94. Warren TL, Dahle CE, Weiner GJ. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. *Clin Lymphoma.* 2000;1:57–61.
  95. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. *Blood.* 1997;89:2994–8.
  96. Betting DJ, Hurvitz SA, Steward KK, Yamada RE, Kafi K, van Rooijen N, et al. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma. *J Immunother.* 2012;35:534–43.